Lung cancer test kit LYOFIA® proGRP

for tumor markersserumplasma

This Progastrin-Releasing Peptide（pro-GRP) POCT Kit is developed for the quantitative detection of Progastrin-Releasing Peptide in samples like human serum and plasma sample by self-developed LYOFIA® system. It's for in vitro diagnostic use only. Summary Lung cancer is the most common primary malignant tumor of the lung. The vast majority of lung cancers originate from the bronchial mucosal epithelium, so it is also called bronchial lung cancer. Lung cancer can spread to the surrounding area and even the whole body. Over the past 50 years, the morbidity and mortality of lung cancer have risen rapidly in countries all over the world, especially in industrialized countries. Lung cancer is currently the number one cause of cancer death,2nd most common cancer worldwide. In 1995, 600,000 people died of lung cancer in the world, and the number is increasing every year. The incidence of lung cancer in women is particularly on the rise. It is the most common cancer in men and the 2nd most common cancer in women after breast cancer. There were more than 2.2 million new cases of lung cancer in 2020. Why Test pro-GRP?product-370-260 There are many cancers that affect the lungs, but we usually use the term “lung cancer” for two main kinds: non-small cell lung cancer (NSCLC) and small cell lung cancer(SCLC). 1.Pro-GRP has been widely considered as sensitive,specific and reliable tumor marker for patients with small cell lung cancer (SCLC), both in limited (LD) and diffuse disease (DD),and a useful tool to discriminate SCLC from NSCLC. 2.Nisman et al. showed that ProGRP had better discriminating power than other tumor markers for detecting SCLC.